Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease.

• Tác giả: Christophe Allais, Charlotte M N Allerton, Annaliesa S Anderson, Joel T Arcari, Lisa M Aschenbrenner, Melissa Avery, Justin Bellenger, Simon Berritt, Britton Boras, Brian P Boscoe, Leanne M Buzon, Rhonda D Cardin, Anthony A Carlo, Karen J Coffman, Alyssa Dantonio, Li Di, Heather Eng, Kathleen A Farley, Rose Ann Ferre, Ketan S Gajiwala, Scott A Gibson, Samantha E Greasley, Brett L Hurst, Eugene P Kadar, Amit S Kalgutkar, Erik A Lachapelle, Lorraine F Lanyon, Jack Lee, Jisun Lee, Yajing Lian, Wei Liu, Luis A Martínez-Alsina, Stephen W Mason, Stephen Noell, Jonathan Novak, R Scott Obach, Keving Ogilvie, Steven V O'Neil, Gregory Ostner, Dafydd R Owen, Nandini C Patel, Martin Pettersson, Devendra K Rai, Matthew R Reese, Sylvie Sakata, Matthew F Sammons, Jean G Sathish, Raman Sharma, Ravi Shankar Singh, Claire M Steppan, Al Stewart, Jamison B Tuttle, Lawrence Updyke, Patrick R Verhoest, Liuqing Wei, Stephen W Wright, Eddie Yang, Qingyi Yang, Yuao Zhu
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Journal of medicinal chemistry , 2025
• Bộ sưu tập: NCBI
• ID: 728305

Tóm tắt

In early 2020, severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infections leading to COVID-19 disease reached a global level leading to the World Health Organization (WHO) declaration of a pandemic. Scientists around the globe rapidly responded to try and discover novel therapeutics and repurpose extant drugs to treat the disease. This work describes the preclinical discovery efforts that led to the invention of PF-07321332 (nirmatrelvir,